Recent Updates
Recently added Catalysts
LXRX

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Friday, March 28, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
Price reaction · baseline $0.3476 (2025-03-27 close) · hit after-hours · 1 other LXRX headline(s) in the window, move may be shared
day 0 close
+64.1%
day 1
+32.6%
day 3
+44.7%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus

Full Press Release Details

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851.
ShareAdd on Google
Tags: LXRX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 28, 2025

Biotech snapshot

Cash runway
$191M liquidity · $3M/mo burn
~61 mo
Minimal dilution risk
Lead asset
SotagliflozinPhase 3
Type 1 Diabetes Mellitus →

Catalyst track record

+111%
best trade around LXRX's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for LXRX.

See every catalyst's timing & PoA →